EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer

Ana Fernández Montes iD, Vicente Alonso Orduña, Elena Asensio Martínez, Nuria Rodríguez Salas, Esperanza Torres, Diego Cacho Lavín, Rosa María Rodríguez Alonso, Esther Falcó, Joan Carles Oliva, Lluis Cirera, Jesus García Gómez, Carles Pericay

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad117 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2023. Verfasst von Ana Fernández Montes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Oncología Médica, Complexo Hospitalario Universitario de Ourense, Calle Ramón Puga Noguerol, Ourense, Spain. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck, Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the mutation. This multicenter, retrospective, cohort study assessed the frequency and prognostic value of specific KRAS mutation codon locations in mCRC patients, and survival outcomes in relation to treatment. Materials and Methods Data from mCRC patients treated in 10 Spanish hospitals between January 2011 and December 2015 were analyzed. The main objective was to investigate (1) the impact of KRAS mutation location on overall survival (OS), and (2) the effect of targeted treatment plus metastasectomy and primary tumor location on OS in patients with KRAS mutations.

Results

The KRAS mutation location was known for 337/2002 patients. Of these, 177 patients received chemotherapy only, 155 received bevacizumab plus chemotherapy, and 5 received anti-epidermal growth factor receptor therapy plus chemotherapy; 94 patients underwent surgery. The most frequent KRAS mutation locations were G12A (33.8%), G12D (21.4%), and G12V (21.4%). Compared with other locations, patients with a G12S mutation had the shortest median OS (10.3 [95% CI, 2.5-18.0] months). OS was longer in patients who underwent surgery versus those who did not, with a trend toward prolonged survival with bevacizumab (median OS 26.7 [95% CI, 21.8-31.7] months) versus chemotherapy alone (median OS 23.2 [95% CI, 19.4-27.0] months).

Conclusion

These findings confirm that KRAS mutation location may predict survival outcomes in patients with mCRC, and suggest that pre-/post-operative bevacizumab plus metastasectomy provides survival benefits in patients with KRAS mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansBevacizumabProto-Oncogene Proteins p21(ras)Retrospective StudiesCohort StudiesPrognosisMutationAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

codoncolonic neoplasmsgenes (ras)mutationprognosis

Substanzen

BevacizumabProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Servicio de Oncología Médica, Complexo Hospitalario Universitario de Ourense, Calle Ramón Puga Noguerol, Ourense, Spain.
  • Servicio de Oncología Médica, Hospital Universitario Miguel Servet, Instituto de Investigacion Sanitaria de Aragon, Paseo Isabel la Católica, Zaragoza, Spain.
  • Servicio de Oncología Médica, Hospital General Universitario de Elche, Carrer Almazara, Elche, Alicante, Spain.
  • Servicio de Oncología Médica, Hospital Universitario La Paz, Paseo de la Castellana, Madrid, Spain.
  • UGC intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria and Instituto de Investigación Biomédica de Málaga (IBIMA), Campus de Teatinos, Málaga, Spain.
  • Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.

ORCID-Profile: Ana Fernández Montes

Förderung

  • Merck
  • Merck KGaA

Zitieren

APA

Fernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., García Gómez, J., & Pericay, C. (2023). The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad117

Vancouver

Fernández Montes A, Alonso Orduña V, Asensio Martínez E, Rodríguez Salas N, Torres E, Cacho Lavín D, et al. The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad117

BibTeX
@article{FernndezMontes2023,
  author = {Fernández Montes, Ana and Alonso Orduña, Vicente and Asensio Martínez, Elena and Rodríguez Salas, Nuria and Torres, Esperanza and Cacho Lavín, Diego and Rodríguez Alonso, Rosa María and Falcó, Esther and Oliva, Joan Carles and Cirera, Lluis and García Gómez, Jesus and Pericay, Carles},
  title = {The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad117}
}
Kostenlos starten →